<DOC>
	<DOCNO>NCT02119715</DOCNO>
	<brief_summary>Neutropenia one frequent adverse effect chemotherapy , main factor limit dosage continuation chemotherapy . A newly pegylated rhG-CSF independently develop JIANGSU HENGRUI Medicine Co. , Ltd , China . Phase 1a , 1b trial show pegylated rhG-CSF decrease renal clearance , increase plasma half-life , prolong efficacy compare rhG-CSF . The purpose study determine safety effectiveness pegylated rhG-CSF prevent neutropenia follow chemotherapy patient breast cancer .</brief_summary>
	<brief_title>A Phase II Study Comparing Pegylated rhG-CSF（HHPG-19K） rhG-CSF Breast Cancer Patients Receiving Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Fever</mesh_term>
	<mesh_term>Febrile Neutropenia</mesh_term>
	<criteria>Pathology diagnosis breast cancer , Chemotherapy naïve ECOG performance status 01 Age 18 70 year Available least 2 cycle consistent neoadjuvant/adjuvant therapy White blood cell ≥ 4.0×109/L ; absolute neutrophil count ≥2.0 × 109/L ; platelet count ≥ 100 × 109/L Alanine aminotransferase ≤1.5×ULN ; aspartate aminotransferase ≤1.5×ULN ; serum creatinine ≤1.5×ULN No obvious cardiac dysfunction Prior bone marrow stem cell transplantation Received systemic antibiotic treatment within 72 h chemotherapy Other disease might influence bone marrow function Radiation therapy within 4 week randomization study Previous exposure allergic Pegylated rhGCSF Pregnancy , lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>Neutropenia</keyword>
	<keyword>Febrile Neutropenia</keyword>
</DOC>